XML 49 R31.htm IDEA: XBRL DOCUMENT v3.25.2
Stock-Based Compensation (Tables)
 9 Months Ended
Jun. 30, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Awards Outstanding
The following table presents a summary of awards outstanding attributable to Arrowhead Pharmaceuticals, Inc.:
June 30, 2025
2013 Plan2021 PlanInducement AwardsTotal
Granted and outstanding awards:
Options850,117 32,151 602,355 1,484,623 
Restricted stock units1,500,000 3,888,660 592,262 5,980,922 
Total2,350,117 3,920,811 1,194,617 7,465,545 
Schedule of Share-Based Payment Arrangement, Expensed
The following table summarizes stock-based compensation expenses included in operating expenses attributable to Arrowhead Pharmaceuticals, Inc.:
Three Months Ended June 30,Nine Months Ended June 30,
2025202420252024
(in thousands)
Research and development$6,898 $6,221 $21,008 $21,634 
General and administrative5,095 8,490 20,242 27,350 
Total$11,993 $14,711 $41,250 $48,984 
Schedule of Summarized Information about Stock Options The following table presents a summary of the stock option activity for the nine months ended June 30, 2025:
SharesWeighted-
Average
Exercise
Price
Per Share		Weighted-
Average
Remaining
Contractual
Term (Years)		Aggregate
Intrinsic
Value
Outstanding at September 30, 2024
1,978,516$23.39 
Granted—— 
Cancelled or expired(35,341)45.92 
Exercised(458,552)7.55 
Outstanding at June 30, 2025
1,484,623$27.75 3.5$5,750,674 
Exercisable at June 30, 2025
1,484,623$27.75 3.5$5,750,674 
Schedule of Share Activity Related to RSUs
The following table summarizes the activity of the Company’s RSUs:
Number of
RSUs		Weighted-
Average
Grant
Date
Fair Value
Per Share
Outstanding at September 30, 2024
4,913,312$49.61 
Granted2,711,00919.49 
Vested(1,383,568)43.96 
Forfeited(259,831)32.96 
Outstanding at June 30, 2025
5,980,922$37.97